Cardio-vascular
Refine Search
Biotechnology
The US regulator has approved Trulicity (dulaglutide) for the reduction of major adverse cardiovascular events (MACE) in certain adults with type 2 diabetes. 24 February 2020
Pharmaceutical
Independent French drugmaker Servier today released financials, showing that revenue in the 2018/19 financial year was 4.62 billion euros ($4.99 billion), an increase of 10.5%. 24 February 2020
Pharmaceutical
Shares of Esperion Therapeutics closed down 8.6% at $61.76 on Friday, despite the company announcing that the US Food and Drug Administration had approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin LDL-Cholesterol (LDL-C) lowering medicine, its first drug to gain regulatory clearance. 24 February 2020
Pharmaceutical
Following a positive recommendation by a European Medicines Agency advisory committee in December for an extended indication, the European Commission (EC) has now granted final approval for Vyndaqel (tafamidis), a once-daily 61mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). 19 February 2020
Pharmaceutical
Application of atherosclerosis drugs for lowering cholesterol is growing, a trend likely to remain more pronounced in developed countries, on the back of unhealthy food habits adopted by individuals and the rising rate of obesity. 14 February 2020
Pharmaceutical
Shares in Anglo-Swedish drugmaker AstraZeneca were nearly 1% lower by Friday lunchtime as the company presented its latest financial results and outlook for the year ahead. 14 February 2020
Biotechnology
As high drug prices continue to incite public outcry and US legislation, it is nonetheless possible that Regeneron Pharmaceuticals’ (Nasdaq: REGN) drug for a rare cholesterol condition could lock in as much as $500,000 annually. 14 February 2020
Pharmaceutical
Big names from the government and life sciences, as well as top brass from Novartis, were in attendance as the Swiss pharma giant marked the official opening of its new UK headquarters. 11 February 2020
Generics
China’s coronavirus pandemic is turning out to be a huge disruptor to India’s $39-billion drug production by severely affecting the flow of imports of active pharmaceutical ingredients (API) and bulk drugs from the country, reports The Pharma Letter’s local correspondent. 7 February 2020
Biotechnology
In the USA, 96.1 million people suffer from hypertension, and another 5.8 million from heart failure. However, investment in new therapies for these chronic diseases is not growing at the rates needed to keep up with the impact they have on human health or the economy, says the latest report from the Biotechnology Innovation Organization (BIO) industry analysis team. 7 February 2020
Biotechnology
Shares of US biotech Regeneron Pharmaceuticals were up 2.64% at $382.00 in early trading, after it reported financial results that beat expectations. 6 February 2020
Pharmaceutical
France’s largest pharma company was able to report a rise in sales in both its annual and quarterly financial results, presented on Thursday morning. 6 February 2020
Biotechnology
A new Sanofi survey has found that only 6% of cardiologists are currently prescribing PCSK9 blockers, while 97% say they are satisfied with outcomes from these treatments. 3 February 2020
Pharmaceutical
At its January meeting, the European Medicines Agency’s Committee for Medicinal Products for Human USE (CHMP) recommended approval of eight novel medicines and one biosimilar. The final decision of the European Commission on the marketing authorization is expected in the coming months. 31 January 2020
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca has agreed to sell the commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chlorthalidone fixed-dose combination), Zestril (lisinopril) and Zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to UK-based Atnahs Pharma. 27 January 2020
Pharmaceutical
British drugmaker AstraZeneca has released top-line results from the Phase III THALES trial comparing Brilinta (ticagrelor) with aspirin. 27 January 2020
Pharmaceutical
The parenteral drugs market – which was worth an estimated $451 billion in 2019 – will be worth $802 billion in 2029, according to a Fact.MR study. 24 January 2020
Biotechnology
Japanese drugmaker Astellas Pharma has sold the stake in its joint venture (JV) with US biotech major Amgen. 23 January 2020
Pharmaceutical
The market for heart failure (HF) therapies is expected to grow from $3.7 billion in 2018 to $22.1 billion in 2028 across the eight major markets (8MM: USA, France, Germany, Italy, Spain, the UK, Japan and China. 20 January 2020
Pharmaceutical
Swiss pharma giant Novartis plans to increase the level of utilization of its Russian plant by almost four-fold until 2022, according to recent statements, made by representatives of the company and some St Petersburg media, reports The Pharma Letter’s local correspondent. 20 January 2020
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze